Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Recruiting2
Not Yet Recruiting1
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT05098210Phase 1Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT04462406Phase 2Active Not Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT07576725Phase 2Not Yet Recruiting

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

NCT07155317Phase 2Recruiting

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Showing all 4 trials

Research Network

Activity Timeline